EUVIMEDEUVIMED entdecken
Crossref

Conversion of Calcitonin into An Oral Dosage Form: Role of Enzyme Inhibitors and Permeation Enhancers in Peptide Hormone Delivery

Rehan Haider *, Zameer Ahmed, Hina Abbas, Shabana Naz Shah, Geetha Kumari Das, Sambreen Zameer

Journal of Thoracic Disease and Cardiothoracic Surgery · 18.02.2026 · 07 (01) · 01-06

DOI: 10.31579/2693-2156/160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thoracic Disease and Cardiothoracic Surgery, online erschienen am 18.02.2026. Verfasst von Rehan Haider * und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calcitonin functions as a peptide hormone that medical professionals commonly apply to treat osteoporosis and Paget's disease, and hypercalcemia because it prevents osteoclasts from breaking down bone. Medical practitioners currently use injectable and intranasal methods to deliver calcitonin because the drug has low oral bioavailability, which results from its enzymatic breakdown and restricted absorption in the intestines. The pharmaceutical industry considers calcitonin delivery through oral routes to be difficult, yet the method brings benefits that include better patient treatment, increased medication usage, and improved patient health results. The review analyzes how recent developments in oral calcitonin formulation research have advanced through enzyme inhibitors and permeation enhancers, which serve as the main technologies for product development. The gastrointestinal tract contains proteolytic enzymes, which include pepsin, trypsin, and chymotrypsin, that quickly destroy peptide hormones. The use of aprotinin and soybean trypsin inhibitor, and protease-resistant formulation matrices as enzyme inhibitors shows potential for maintaining calcitonin integrity. Permeation enhancers, including medium-chain fatty acids, bile salts, surfactants, and chitosan derivatives, permanently enhance epithelial permeability, which enables transcellular and paracellular transport. The research demonstrates that enzyme inhibition methods, which combine with permeability enhancement techniques, lead to better oral calcitonin absorption results when applied through proper optimization methods that maintain intestinal safety. The article presents a review that examines formulation methods and their impact on pharmacokinetics and safety assessments, and the difficulties of translating research findings into real-world applications. The evidence supports the use of oral calcitonin as a valid treatment option when delivery systems are developed to achieve both effective results and tolerance by mucosal tissues. The development of new peptide drug delivery methods will make oral calcitonin administration possible in normal clinical settings.

Zitieren

APA

*, R. H., Ahmed, Z., Abbas, H., Shah, S. N., Das, G. K., & Zameer, S. (2026). Conversion of Calcitonin into An Oral Dosage Form: Role of Enzyme Inhibitors and Permeation Enhancers in Peptide Hormone Delivery. Journal of Thoracic Disease and Cardiothoracic Surgery, 07(01), 01-06. https://doi.org/10.31579/2693-2156/160

Vancouver

* RH, Ahmed Z, Abbas H, Shah SN, Das GK, Zameer S. Conversion of Calcitonin into An Oral Dosage Form: Role of Enzyme Inhibitors and Permeation Enhancers in Peptide Hormone Delivery. Journal of Thoracic Disease and Cardiothoracic Surgery. 2026;07(01):01-06. doi:10.31579/2693-2156/160

BibTeX
@article{2026,
  author = {*, Rehan Haider and Ahmed, Zameer and Abbas, Hina and Shah, Shabana Naz and Das, Geetha Kumari and Zameer, Sambreen},
  title = {Conversion of Calcitonin into An Oral Dosage Form: Role of Enzyme Inhibitors and Permeation Enhancers in Peptide Hormone Delivery},
  journal = {Journal of Thoracic Disease and Cardiothoracic Surgery},
  year = {2026},
  volume = {07},
  number = {01},
  pages = {01--06},
  doi = {10.31579/2693-2156/160}
}
Kostenlos starten →